Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 antibody response after a booster dose of BNT162b2 in Thai children and adolescents
TCTR20230424002Phase 4Completed
- Sponsor
- Siriraj Research Development Fund
- Start
- May 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Siriraj Research Development Fund. Primary endpoint: SARS-CoV-2 antibody response. Started May 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20230424002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230424002.